Publications by authors named "B Gruson"
Article Synopsis
- Ruxolitinib is an effective treatment for steroid-refractory graft-versus-host disease (SR-GVHD), with overall response rates exceeding 70%, but it increases the risk of cytomegalovirus (CMV) reactivation.
- A study of 57 patients showed that starting ruxolitinib significantly raised the chances of first CMV (HR=1.747) and Epstein-Barr virus (EBV) reactivation (HR=2.657).
- Despite the risk of viral reactivation, ruxolitinib's benefits in treating SR-GVHD are substantial, highlighting the need for careful monitoring of viral loads rather than restricting its use.
Article Synopsis
- Thrombocytopenia in MDS and CMML:
- Despite being moderate in prevalence for low-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia (CMML), thrombocytopenia poses significant risks for severe bleeding, and current treatment options remain limited.
- Efficacy of Eltrombopag (ELT):
- In a retrospective study involving 61 patients (50 with MDS and 11 with CMML), ELT demonstrated a platelet response in 77% of patients, with a median duration of response lasting about 8 months, and none of the patients who stopped treatment relapsed within a follow-up period.
- Safety and Comp
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with poor prognosis and no treatment consensus. Combining chemotherapy and immunotherapy is a promising strategy to enhance therapeutic effect. Before combining these therapies, the influence of one on the other has to be explored.
View Article and Find Full Text PDF